| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Financial Officer | EVP, Chief Financial Officer | Chief Financial Officer
1 company
Mark C. Schneyer is EVP, Chief Financial Officer at ACAD. Mark C. Schneyer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.5M at current prices.
Our model assigns Mark C. Schneyer a middling insider score of 57/100, based on 28 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -6.0%.
The ACAD filings lean toward selling, a net 153,455 shares.
Mark C. Schneyer has 31 Form 4 filings on record from February 2022 to October 2026, all as EVP, Chief Financial Officer at ACADIA Pharmaceuticals (ACAD), 2022–2026.
The 74 reported transactions were 32 open-market sales, 27 option exercises, 10 option or other derivative awards and 5 stock awards.
Counted by filing, the open-market trades come to no purchases and 28 sales worth about $3.4M.
The largest open-market sale was 20,141 shares of ACAD at an average $29.16 on August 6, 2026, about $587K.
4 of the 25 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 21 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | ACAD Acadia Pharmaceuticals Inc. | EVP, Chief Financial Officer | Sell | 3,321 | $20.88 | $69,342.48 | -4.4% | - | - | |
| Aug 6, 2026 | ACAD Acadia Pharmaceuticals Inc. | EVP, Chief Financial Officer | Sale+OE10b5-1 | 20,141 | $29.16 | $587,242.01 | -22.9% | - | - | |
| May 4, 2026 | ACAD Acadia Pharmaceuticals Inc. | EVP, Chief Financial Officer | Sale+OE | 3,506 | $21.79 | $76,395.74 | -5.0% | +15.4% | - | |
| Apr 7, 2026 | ACAD Acadia Pharmaceuticals Inc. | EVP, Chief Financial Officer | Sale+OE | 2,709 | $22.20 | $60,139.80 | -4.1% | +16.7% | - | |
| Mar 26, 2026 | ACAD Acadia Pharmaceuticals Inc. | EVP, Chief Financial Officer | Sale+OE | 7,385 | $21.55 | $159,135.88 | -10.9% | +8.8% | - | |
| Nov 18, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 10,262 | $23.69 | $243,113.96 | -16.1% | -3.6% | - | |
| Sep 15, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sell | 3,498 | $23.65 | $82,727.70 | -7.5% | +10.5% | +8.5% | |
| Aug 18, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sell10b5-1 | 22,000 | $25.18 | $554,023.80 | -35.4% | -4.2% | +20.4% | |
| May 16, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sell10b5-1 | 2,000 | $25.00 | $50,000.00 | -3.1% | +10.2% | - | |
| May 2, 2025 | ACAD Acadia Pharmaceuticals Inc | EVP, Chief Financial Officer | Sale+OE | 3,498 | $14.60 | $51,070.80 | -5.3% | +59.8% | - |